GDNF

Glial Cell Line-Derived Neurotrophic Factor (GDNF) is a potent neurotrophic factor that supports the maintenance and survival of mid-brain dopaminergic and spinal motor neurons through specific signaling pathways involving the Ret proto-oncogene and GFRα1 PMID 39456173. Recognized as an exerkine due to its intensity-dependent upregulation in skeletal muscle and the spinal cord following physical activity, GDNF offers significant therapeutic potential for neuroprotection and neurorestoration in Parkinson's and Alzheimer's diseases PMID 39456173PMID 38393277PMID 34782555.

• Neuron Maintenance and Survival: It is a crucial participant in maintaining mid-brain dopaminergic neurons and spinal motor neurons PMID 39456173. It has been demonstrated to rescue neurons from both naturally occurring cell death and axotomy-induced (severed axon) cell death, while also promoting gliogenesis PMID 39456173.
• Signaling Mechanism: The Ret proto-oncogene serves as the signaling receptor for GDNF,requiring an accessory protein known as GDNF family receptor α1 (GFRα1) for effective receptor activation PMID 39456173.

GDNF is classified as an exerkine because its expression in skeletal muscle and the spinal cord is modulated by physical activity, following a dose-response pattern based on exercise intensity.

• Muscle Secretion & Intensity Dependence: Exercise leads to elevated GDNF protein concentrations in skeletal muscle, which can then be released into the bloodstream to potentially cross the blood–brain barrier (BBB) and reach the CNS PMID 38393277. The response is intensity-specific:
• Low-intensity exercise increases GDNF in slow-twitch muscles (e.g., soleus) while decreasing it in fast-twitch muscles PMID 38393277.
• High-intensity exerciserecruits fast-twitch muscles in mouse models, leading to hypertrophy and increased GDNF content PMID 38393277.
• Spinal Cord Regulation: Short-term exercise has also been observed to directly increase GDNF protein levels within the spinal cord PMID 39456173.

• Parkinson’s Disease (PD): GDNF levels are notably reduced in the substantia nigra of patients with PD. Because GDNF promotes the survival of dopaminergic neurons, it holds both neuroprotective (protecting against damage) and neurorestorative (repairing damage) potential for PD therapy with clinical trials testing GDNF therapy for PD being currently underway PMID 39456173.
• Alzheimer’s Disease (AD): In preclinical models, BDNF/IGF-1/GDNF-secreting cells have been shown to rescue cultured rat septal neurons from toxicity induced by Amyloid-β, suggesting a protective role against AD pathology alongside other exerkines PMID 34782555.

1. Parkinson’s Disease (PD)

• Gene Therapy: Recent Phase 1b clinical trials of AAV2-GDNF (intraputaminal infusion) demonstrated safety and stability in mild PD, with some clinical improvements in moderate cohorts over 18 months PMID 40395017. Long-term follow-up (45 months) confirmed persistent transgene expression and dopaminergic sprouting PMID 38718138. However, off-target delivery remains a concern, with leakage into the caudate nucleus noted in some patients PMID 40932279.
• Pharmacological Stimulation: To bypass surgical delivery, researchers are exploring small molecules like Ibudilast (a PDE inhibitor) and Gemfibrozil (via PPARα), which upregulate endogenous GDNF and protect dopaminergic neurons in preclinical models PMID 41382340PMID 33514677.
• Novel Delivery Systems: Innovative delivery methods include macrophage-derived extracellular vesicles (EVs) PMID 35741061, hyaluronic acid-based hydrogels loaded with mesenchymal stem cells (MSCs) PMID 41205932, and cryogel microcarriers PMID 39231475.
• Efficacy Barriers: The failure of some clinical trials may be attributed to the downregulation of the GDNF receptor, RET, or the transcription factor NURR1 in diseased neurons, which limits GDNF's neurorestorative capacity PMID 37178997PMID 33935108PMID 33716718.

2. Other Neurodegenerative Conditions

• Alzheimer’s Disease (AD): Overexpression of GDNF in astrocytes increased branching and partially preserved memory function in rat models PMID 40456763.
• Amyotrophic Lateral Sclerosis (ALS): Human neural progenitor cells secreting GDNF (iNPC-GDNF) preserved motor neurons in spinal cord models PMID 37084724. The drug Edaravone appears to exert neuroprotection by activating the GDNF/RET signaling pathway PMID 35012575.
• Gaucher Disease: A double-gene therapy (AAV9-GBA1-GDNF) successfully prevented neuronal death and recovered motor ability in murine models PMID 40206656.
• Multiple Sclerosis (MS): Reduced circulating GDNF is observed in MS patients, suggesting its potential as a biomarker and therapeutic target PMID 39451573.

3. Psychiatric Disorders and Addiction

• Depression & Schizophrenia: Meta-analyses indicate that circulating GDNF levels are significantly reduced in patients with Major Depressive Disorder (MDD) and schizophrenia, and these levels increase following therapeutic interventions PMID 40992107PMID 39881227. Computerized cognitive remediation therapy was shown to restore serum GDNF levels in schizophrenia patients PMID 39886050.
• Addiction: GDNF gene therapy in the ventral tegmental area (VTA) prevented relapse in alcohol use disorder models in primates PMID 37580533. Conversely, GDNF may contribute to alcohol-induced liver injury via NF-κB activation PMID 35338490. In methamphetamine toxicity, targeting RET-mediated endocytosis of GDNF is key to neuroprotection PMID 41096789. Ultrasound combined with GDNF-loaded microbubbles has been used to target the blood-brain barrier for addiction treatment PMID 36046678.

4. Regenerative Medicine and Peripheral Repair

• Spinal Cord Injury (SCI): Functional scaffolds releasing GDNF promote neurogenesis, axonogenesis, and remyelination, improving motor recovery PMID 38615813PMID 39968499.
• Renal Fibrosis: GDNF-modified MSCs and extracellular vesicles enhance renal microcirculation and inhibit fibrosis via the PI3K/Akt pathway PMID 33413640PMID 39460807PMID 38086618.
• Retinal Degeneration: Stem cell therapies combined with GDNF protect photoreceptors and improve visual function in degenerative models PMID 37786347PMID 33440745.
• Gut Motility: GDNF improves colonic motility and alleviates constipation in colitis and PD models, partly through Connexin 43 (Cx43) regulation PMID 40062335PMID 39158627.

5. Oncology: A Double-Edged Sword

• Tumor Promotion: GDNF/RET signaling promotes resistance to chemotherapy and radiotherapy in glioblastoma PMID 39085346 and drives perineural invasion and metastasis in pancreatic cancer PMID 39020072. In breast cancer, high RET/GDNF expression correlates with endocrine resistance and poor survival PMID 37061618.
• Tumor Suppression: Conversely, the long non-coding RNA GDNF-AS1 (antisense RNA) was found to inhibit glioma progression by inducing ferroptosis PMID 41275921. Additionally, GFRα4 is being explored as a target for CAR T-cell immunotherapy in medullary thyroid carcinoma PMID 33614919.

6. Emerging Isoforms

• Research into alternative splicing has identified a small, bioactive peptide isoform, djGDNF47, which possesses neuroinductive properties and offers a potentially more manageable therapeutic alternative to full-length GDNF PMID 40473167PMID 41527797.